D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Related Keywords

,Subcutaneous Daratumumab ,Autologous Stem Cell Transplant ,Daratumumab ,Bortezomib ,Lenalidomide ,Nd Dexamethasone Consolidation ,Daratumumab Lenalidomide Maintenance ,Patients With Newly Diagnosed ,Transplant Eligible Multiple Myeloma ,Perseus Trial ,Nct03710603 ,Pieter Sonneveld ,D ,Erasmus Mc Cancer Institute ,